Pharmacokinetics of injectable favipiravir: phase I, randomized, double-blind, placebo-controlled study in healthy East Asian subjects.

In 30 seconds

This phase I, randomized, double-blind, placebo-controlled trial evaluated the pharmacokinetics and tolerability of injectable favipiravir in healthy East Asian subjects. A single intravenous dose of up to 2,400 mg resulted in a geometric mean maximum plasma concentration of 126 μg/mL. The study supports further clinical evaluation of this injectable formulation.

Key findings

• The maximum plasma concentration after a single 2,400 mg dose was 126 μg/mL.
• Trough plasma concentrations in the IV cohort were maintained at approximately 85 μg/mL after Day 2.
• Plasma concentrations from the injectable formulation were about 20% higher than those from oral doses.

Why it matters

Understanding the pharmacokinetics of injectable favipiravir is crucial for optimizing treatment protocols, especially for conditions like severe fever with thrombocytopenia syndrome. This research may inform future clinical applications and dosing strategies.